Allogene Therapeutics, Inc.
ALLONASDAQHealthcare● Active
$1.85
$-0.03(-1.60%)
Market Cap$451158381
P/E Ratio—
52W High$4.46
52W Low$0.98
Allogene Therapeutics, Inc. (ALLO) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ALLO · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.11B |
| Cost of Revenue | $0.01B | $0.00B | $0.00B | $0.01B | $0.00B |
| Gross Profit | ($0.01B) | $0.00B | $0.00B | ($0.01B) | $0.11B |
| Gross Margin %(computed) | — | 100.00% | 100.00% | — | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $0.15B | $0.19B | $0.24B | $0.26B | $0.22B |
| G&A Expenses | $0.06B | $0.07B | $0.07B | $0.08B | $0.07B |
| Total Operating Expenses | $0.19B | $0.27B | $0.33B | $0.32B | $0.29B |
| Operating Income | ($0.21B) | ($0.27B) | ($0.33B) | ($0.34B) | ($0.18B) |
| Operating Margin %(computed) | — | — | — | — | -157.94% |
| Interest Income | $0.02B | $0.02B | $0.02B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.19B) | ($0.26B) | ($0.33B) | ($0.34B) | ($0.18B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.19B) | ($0.26B) | ($0.33B) | ($0.34B) | ($0.18B) |
| Net Margin %(computed) | — | — | — | — | -159.57% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.87 | $-1.32 | $-2.09 | $-2.38 | $-1.34 |
| Wtd Avg Shares | 0.22B | 0.19B | 0.16B | 0.14B | 0.14B |
| EBITDA | ($0.19B) | ($0.24B) | ($0.31B) | ($0.32B) | ($0.17B) |
| EBITDA Margin %(computed) | — | — | — | — | -148.78% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Allogene Therapeutics, Inc. data
About Allogene Therapeutics, Inc. (ALLO) Income Statement
Allogene Therapeutics, Inc. (ALLO) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ALLO reported revenue of $0.00B, gross profit of ($0.01B) (gross margin —), and net income of ($0.19B) — a net profit margin of —.
Frequently asked questions
ALLO · 4 questionsAllogene Therapeutics, Inc. (ALLO) reported revenue of $0.00B for 2025, down 100.0% year-over-year.
ALLO revenueALLO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08